NASHUA, N.H. – January 27, 2019 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced it will showcase its latest advancements in cancer detection and therapy, including ProFound AI™ and the Xoft® Axxent® Electronic Brachytherapy (eBx®) System®, in the iCAD exhibition booth (# S1.C71) at Arab Health 2020 in Dubai from January 27-30. Arab Health is the largest gathering of healthcare companies, technologies, products and services in the Middle East and North African (MENA) region.

"This medical meeting represents a significant milestone for the Company, as it is the first time iCAD's technologies for both the detection and treatment of cancer will be exhibited together in the Middle East, where breast cancer rates are expected to double between 2012 and 2030 - the highest relative increase of any region globally,"1 according to Michael Klein, Chairman and CEO of iCAD. "A growing body of evidence suggests early cancer diagnosis leads to better outcomes,2,3,4 and demand continues to grow for increasingly targeted, more personalized treatment options. iCAD's technology is congruent with both of these trending forces in healthcare today."

iCAD's Breast Health Solutions suite includes ProFound AI for Digital Breast Tomosynthesis (DBT), as well as software solutions for 2D mammography and breast density. ProFound AI is a high-performing workflow solution featuring the latest in deep-learning artificial intelligence capabilities. In December 2018, ProFound AI for DBT became the first artificial intelligence software for DBT to be cleared by the U.S. Food and Drug Administration; it was also CE marked and Health Canada licensed that same year. ProFound AI for 2D Mammography was CE marked in July 2019.
Intended to be used by radiologists reviewing mammography or DBT images, ProFound AI rapidly and accurately analyzes each individual image, or slice, and identifies potentially malignant lesions. Trained with one of the largest available image datasets, it provides radiologists with crucial information, such as Certainty of Finding lesion and Case Scores, which assists in clinical decision-making and prioritizing caseloads. The technology also allows for continuously improved performance via ongoing product updates.

Positive clinical data from a large reader study involving ProFound AI for DBT were recently published in Radiology: Artificial Intelligence.5 According to study findings, ProFound AI for DBT improved radiologist sensitivity by 8 percent, reduced unnecessary patient recall rates by 7.2 percent, and slashed reading time for radiologists by 52.7 percent.5 Additionally, ProFound AI for DBT cut reading time by up to 57.4 percent for radiologists reading cases with dense breasts.6

Products and Clearances Homepage